{"result": {"id": "d1c84a6f-eefe-4188-8f11-95f2cae1c856", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>CYP2D6<|>organization<|>CYP2D6 is a liver enzyme responsible for metabolizing certain drugs like metoprolol>  \n##  \n(\"entity\"<|>CYP2C8<|>organization<|>CYP2C8 is a liver enzyme that metabolizes drugs like rosiglitazone and repaglinide, inhibited by gemfibrozil metabolites>  \n##  \n(\"entity\"<|>UGT<|>organization<|>UGT (UDP-glucuronosyltransferase) is an enzyme system involved in drug metabolism, including gemfibrozil>  \n##  \n(\"entity\"<|>OATP1B1<|>organization<|>OATP1B1 is a liver transporter protein that affects statin drug absorption and metabolism>  \n##  \n(\"entity\"<|>CYP450<|>organization<|>CYP450 is a family of liver enzymes involved in drug metabolism, including warfarin>  \n##  \n(\"entity\"<|>CYP2C9<|>organization<|>CYP2C9 is a liver enzyme that primarily metabolizes S-warfarin>  \n##  \n(\"entity\"<|>CYP1A2<|>organization<|>CYP1A2 is a liver enzyme involved in metabolizing R-warfarin>  \n##  \n(\"entity\"<|>CYP3A4<|>organization<|>CYP3A4 is a liver enzyme involved in metabolizing R-warfarin>  \n##  \n(\"entity\"<|>CYP2C19<|>organization<|>CYP2C19 is a liver enzyme involved in metabolizing R-warfarin>  \n##  \n(\"relationship\"<|>普罗帕酮<|>CYP2D6<|>Propafenone inhibits CYP2D6, slowing metoprolol metabolism<|>8>  \n##  \n(\"relationship\"<|>吉非罗齐<|>CYP2C8<|>Gemfibrozil metabolites irreversibly inhibit CYP2C8, affecting drugs metabolized by this enzyme<|>7>  \n##  \n(\"relationship\"<|>吉非罗齐<|>UGT<|>Gemfibrozil is metabolized by UGT enzymes<|>6>  \n##  \n(\"relationship\"<|>环孢素<|>OATP1B1<|>Cyclosporine inhibits OATP1B1 transporter, increasing statin toxicity risk<|>7>  \n##  \n(\"relationship\"<|>华法林<|>CYP2C9<|>S-warfarin is primarily metabolized by CYP2C9<|>8>  \n##  \n(\"relationship\"<|>华法林<|>CYP1A2<|>R-warfarin is partially metabolized by CYP1A2<|>6>  \n##  \n(\"relationship\"<|>华法林<|>CYP3A4<|>R-warfarin is partially metabolized by CYP3A4<|>6>  \n##  \n(\"relationship\"<|>华法林<|>CYP2C19<|>R-warfarin is partially metabolized by CYP2C19<|>6>  \n##  \n(\"relationship\"<|>非诺贝特<|>CYP2C8<|>Fenofibrate does not inhibit CYP2C8, unlike gemfibrozil<|>5>  \n##  \n(\"relationship\"<|>非诺贝特<|>UGT<|>Fenofibrate does not inhibit UGT enzymes<|>5>  \n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1752166555, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 801, "prompt_tokens": 3700, "total_tokens": 4501, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 3648}, "prompt_cache_hit_tokens": 3648, "prompt_cache_miss_tokens": 52}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: �增加梅美 托洛尔的不良 反应\t根据说明书： “合用普罗帕酮使美托洛尔 的血药浓度增加 2 ～ 5 倍”\t普罗帕酮抑制 CYP2D6，减慢美托洛尔 的代谢\t避免合用\n美托洛尔\t维拉帕米\t心动过缓和低 血压\t根据说明书： “合用可能导致心动过缓和 血压下降”\t维拉帕米和美托洛尔合用对方式传导和 窦房结功能有相加的抑制作用\t避免合用\n注：ACEI= 血管紧张素转化酶抑制剂，eGFR= 估算肾小球滤过率，CYP450= 细胞色素 P450\n\n\n　　他汀类药物均是 OATP1B1 底物，与 OATP1B1 抑制 剂如环孢素合用时增加横纹肌溶解症的风险，临床应避 免合用。瑞舒伐他汀、普伐他汀和匹伐他汀在体内较少 被代谢，但是与 OATP1B1 抑制剂环孢素合用仍然存在 严重的相互作用。\n4.3.2    苯氧酸类（ 贝特类）  吉非罗齐在体内经 UGT 代谢后， 代谢产物不可逆地抑制 CYP2C8 ，与其他经 CYP2C8 代谢的药物（ 如罗格列酮、瑞格列奈等）产生 相互作用。与西立伐他汀联用有致横纹肌溶解的报道， 临床应该禁止合用。 非诺贝特对 UGT 和 CYP2C8 没有 抑制作用，药物相互作用极少见。\n4.3.3    胆酸螯合剂（树脂类）  胆酸螯合剂具有非选择 性吸附作用，影响一些酸性药物如氢氯噻嗪、华法林及  地高辛的肠道吸收，降低其AUC，影响疗效。与考来烯胺、 考来替泊相比，考来维仑与其他药物相互作用少见。\n4.3.4    胆固醇吸收抑制剂  依折麦布没有诱导肝脏 CYP450 酶的作用，不影响氨苯砜、右美沙芬、地高辛、 口服避孕药等的药动学。\n　　血脂调节药相关药物相互作用的潜在危害及处置见 表 3。\n4.4    心血管病治疗用药  硝酸酯类药物的代谢不涉及\n\n\nCYP450 酶，较少发生药动学相互作用。但是与其他扩 张血管药物（如西地那非、伐地那非、他达拉非等）合 用存在药效学的相互作用，可导致严重的低血压风险， 临床应该禁止合用。\n　　心血管病治疗用药相关药物相互作用的潜在危害及 处置见表 4。\n4.5    抗血小板及抗凝药\n4.5.1    华法林  华法林是 S- 华法林和R- 华法林的光学 异构体混合物。其中 S- 华法林的活性占 75% ，在体内 主要经过 CYP2C9 代谢，R- 华法林主要经过 CYP1A2 、 CYP3A4 、CYP2C19 代谢。 能够�\n######################\nOutput:", "role": "user"}, {"role": "assistant", "content": "(\"entity\"<|>美托洛尔<|>person<|>美托洛尔是一种药物，与普罗帕酮或维拉帕米合用时可能增加不良反应的风险，如心动过缓和低血压>  \n##  \n(\"entity\"<|>普罗帕酮<|>person<|>普罗帕酮是一种药物，通过抑制CYP2D6酶减慢美托洛尔的代谢，增加其血药浓度>  \n##  \n(\"entity\"<|>维拉帕米<|>person<|>维拉帕米是一种药物，与美托洛尔合用时可能对心脏传导和窦房结功能产生相加的抑制作用，导致心动过缓和血压下降>  \n##  \n(\"entity\"<|>环孢素<|>person<|>环孢素是一种OATP1B1抑制剂，与他汀类药物合用时可能增加横纹肌溶解症的风险>  \n##  \n(\"entity\"<|>瑞舒伐他汀<|>person<|>瑞舒伐他汀是一种他汀类药物，较少被代谢，但与OATP1B1抑制剂环孢素合用时仍存在严重相互作用>  \n##  \n(\"entity\"<|>普伐他汀<|>person<|>普伐他汀是一种他汀类药物，较少被代谢，但与OATP1B1抑制剂环孢素合用时仍存在严重相互作用>  \n##  \n(\"entity\"<|>匹伐他汀<|>person<|>匹伐他汀是一种他汀类药物，较少被代谢，但与OATP1B1抑制剂环孢素合用时仍存在严重相互作用>  \n##  \n(\"entity\"<|>吉非罗齐<|>person<|>吉非罗齐是一种贝特类药物，经UGT代谢后可抑制CYP2C8，与其他经CYP2C8代谢的药物（如罗格列酮、瑞格列奈）产生相互作用>  \n##  \n(\"entity\"<|>西立伐他汀<|>person<|>西立伐他汀是一种他汀类药物，与吉非罗齐联用有致横纹肌溶解的报道>  \n##  \n(\"entity\"<|>非诺贝特<|>person<|>非诺贝特是一种贝特类药物，对UGT和CYP2C8没有抑制作用，药物相互作用极少见>  \n##  \n(\"entity\"<|>考来烯胺<|>person<|>考来烯胺是一种胆酸螯合剂，具有非选择性吸附作用，可能影响酸性药物（如氢氯噻嗪、华法林、地高辛）的肠道吸收>  \n##  \n(\"entity\"<|>考来替泊<|>person<|>考来替泊是一种胆酸螯合剂，具有非选择性吸附作用，可能影响酸性药物（如氢氯噻嗪、华法林、地高辛）的肠道吸收>  \n##  \n(\"entity\"<|>考来维仑<|>person<|>考来维仑是一种胆酸螯合剂，与其他药物相互作用少见>  \n##  \n(\"entity\"<|>依折麦布<|>person<|>依折麦布是一种胆固醇吸收抑制剂，不诱导肝脏CYP450酶，不影响其他药物的药动学>  \n##  \n(\"entity\"<|>华法林<|>person<|>华法林是一种抗凝药，由S-华法林和R-华法林组成，分别通过CYP2C9和CYP1A2、CYP3A4、CYP2C19代谢>  \n##  \n(\"relationship\"<|>普罗帕酮<|>美托洛尔<|>普罗帕酮抑制CYP2D6，减慢美托洛尔的代谢，增加其血药浓度<|>8>  \n##  \n(\"relationship\"<|>维拉帕米<|>美托洛尔<|>维拉帕米与美托洛尔合用可能导致心动过缓和血压下降<|>7>  \n##  \n(\"relationship\"<|>环孢素<|>瑞舒伐他汀<|>环孢素作为OATP1B1抑制剂，与瑞舒伐他汀合用可能增加横纹肌溶解症的风险<|>6>  \n##  \n(\"relationship\"<|>环孢素<|>普伐他汀<|>环孢素作为OATP1B1抑制剂，与普伐他汀合用可能增加横纹肌溶解症的风险<|>6>  \n##  \n(\"relationship\"<|>环孢素<|>匹伐他汀<|>环孢素作为OATP1B1抑制剂，与匹伐他汀合用可能增加横纹肌溶解症的风险<|>6>  \n##  \n(\"relationship\"<|>吉非罗齐<|>西立伐他汀<|>吉非罗齐与西立伐他汀联用有致横纹肌溶解的报道<|>7>  \n##  \n(\"relationship\"<|>考来烯胺<|>华法林<|>考来烯胺可能影响华法林的肠道吸收，降低其AUC<|>5>  \n##  \n(\"relationship\"<|>考来替泊<|>华法林<|>考来替泊可能影响华法林的肠道吸收，降低其AUC<|>5>  \n<|COMPLETE|>"}, {"content": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": null, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_extract-continuation-0_fd73dca59ba95351f8387c1a53ca2472c14f61182421224af43beb476645f0b2_v2"}